Adaptimmune Therapeutics plc
https://www.adaptimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adaptimmune Therapeutics plc
CDR-Life Raises $76m To Develop Next-Generation T-Cell Engagers
The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.
Stock Watch: Brace For European Biotech Departures From NASDAQ
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Cutting-Edge Biologics Approvals, Trials Pick Up In Korea After New Law
Novartis among the first to benefit with approvals for Zolgensma, Kymriah, and Luxturna. The new law has also enabled its first clinical trial – a Phase Ib study by Seoul National University of a CAR-T therapy for recurrent or refractory, CD19-positive, B-cell acute lymphoblastic leukemia.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Adaptimmune LLC
- Adaptimmune Ltd.